Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Some pitfalls in selecting descriptive pharmacokinetic models.

T B Vree, Y A Hekster, M J Oosterbaan

    Drug Intelligence & Clinical Pharmacy
    |September 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    HPLC analysis and pharmacokinetics of the enantiomers of R,S-oxazepam and R,S-temazepam with their corresponding glucuronide conjugates in urine and plasma of man.

    Acta neuropsychiatrica·2016
    Same author

    Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites.

    Pharmaceutical research·2013
    Same author

    Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery.

    Clinical drug investigation·2008
    Same author

    Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not.

    Pharmacoepidemiology and drug safety·2004
    Same author

    Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.

    International journal of clinical pharmacology and therapeutics·2004
    Same author

    [A patient with lessened sensitivity to acenocoumarol during a period of enteral feeding].

    Nederlands tijdschrift voor geneeskunde·2004

    Selecting appropriate pharmacokinetic models is crucial. A two-compartment model isn't always best for biphasic drug concentrations; metabolite kinetics and elimination pathways can necessitate different models.

    Area of Science:

    • Pharmacokinetics and Drug Metabolism
    • Pharmacological Modeling

    Background:

    • Selecting appropriate pharmacokinetic models is essential for accurate drug parameter calculation.
    • Biphasic plasma concentration-time curves can arise from various physiological processes.
    • Misapplication of models can lead to incorrect interpretations of drug behavior.

    Purpose of the Study:

    • To identify common pitfalls in selecting pharmacokinetic models.
    • To discuss the appropriateness of the two-compartment model for biphasic drug concentration-time profiles.
    • To explore alternative explanations for convex and concave biphasic curves.

    Main Methods:

    • Enumeration of common selection errors for pharmacokinetic models.
    • Analysis of drug concentration-time data exhibiting biphasic profiles.

    Related Experiment Videos

  • Consideration of parent drug and metabolite kinetics.
  • Evaluation of metabolic elimination and renal excretion factors.

    • Main Results:

    • A two-compartment model is not universally suitable for all biphasic convex curves, especially when metabolite kinetics are involved.
    • Metabolic equilibrium does not automatically mandate a two-compartment model.
    • Capacity-limited metabolism is not the sole cause of concave biphasic curves; renal excretion and bioavailability limitations are also key factors.
    • Sulfonamides were used to illustrate convex and concave biphasic curves.

    Conclusions:

    • Careful consideration of drug metabolite kinetics and elimination pathways is vital when selecting pharmacokinetic models.
    • Alternative factors beyond simple metabolic conversion should be investigated for concave biphasic drug profiles.
    • Accurate pharmacokinetic modeling requires a nuanced approach tailored to specific drug characteristics.